A Phase II, Randomized, Active Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use.

Trial Profile

A Phase II, Randomized, Active Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Etravirine; HIV protease inhibitors
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Oct 2009 Actual end date (Jun 2006) added as reported by ClinicalTrials.gov.
    • 01 Nov 2008 Results published in HIV Medicine, according to 1129114.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top